SNX17

Across TCGA pan-cancer cohorts, SNX17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNX17 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SNX17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SNX17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where SNX17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.866	0.490	<.001	77	view →
PDAC	DFS	Tertile	III,IV	0.118	0.566	.004	31	view →
LSCC	OS	Median	All	0.938	1.000	.012	28	view →
UCEC	DFS	Median	II,III,IV	0.538	0.862	.048	4	view →
LUAD	DFS	Quartile	All	0.763	0.464	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNX17–CCRCC (DFS)

Open the CCRCC breakdown →